McFadyens Join Fight To Get Government Funding For Boy's Treatment

-178677_ORIGINALCAMPBELLFORD – A Campbellford family knows all too well the effects of MPS VI (Maroteaux Lamy Syndrome), a rare enzyme deficiency.

Seven-year-old Isaac McFadyen -the son of Andrew and Ellen and brother of Gabriel -is one of eight confirmed cases in Canada (and 1,100 worldwide) who have the progressive disease. Symptoms include stiffening joints, stunted growth, heart and airway disease, spinal cord compression and a shortened life span.

The McFadyens also know how much treatment has helped Isaac — a treatment he gets only because of provincial funding. Funding they had to lobby to get.

About five years after Isaac’s diagnosis, a Palmerston, Ontario family is going through a similar experience. Darren and Pam More’s two-year-old son, Jasper, was diagnosed with MPS VI six weeks ago. They learned Monday that Jasper was denied funding to receive the treatment.

“It’s shocking in our province right now that this is taking place. We do have precedent set with Isaac and it’s virtually an identical case,” Andrew McFadyen said on Tuesday. “We know through Isaac’s precedent that they are… paying for it at the government level and it’s been very obvious how important that treatment has been to Isaac. For them to be putting the (More) family off right now and telling them no he’s not getting funded… to me it’s a travesty and it’s not representing equal access to health care for everybody.”

However, Health Minister Deb Matthews noted in an interview with QMI Agency on Wednesday the laws in Ontario changed in 2006 to prevent politicians from choosing which drugs do or don’t get covered. Now, the decision rests with an executive officer who relies on a panel of experts that weights medical evidence.

“However, I do want to learn more about this and I need to understand the basis of the decision,” Matthews said.

The McFadyens established The Isaac Foundation in 2006 to help raise awareness and also raise money to help fund innovative research projects (more than $240,000 has been given out) which aim to find a cure for MPS VI.

There is no known cure yet for MPS VI, but there is the life-sustaining treatment available called Naglazyme, which is an Enzyme Replacement Therapy designed to provide patients with a synthetic version of the enzyme they are lacking. Small doses are infused into the patient’s bloodstream.

“Studies are showing right now that kids that get on this treatment at a young age, basically where Jasper is, it gives them a better opportunity to prevent some of the side effects that come with the disease,” McFadyen said. “You can slow the progression of the disease, but it’s very, very difficult to reverse any of the symptoms that you’ve already seen, so in Isaac’s case he did start early but there was still a lot of disease in him beforehand and he had to have the spinal cord decompression surgery.

“Children diagnosed before age of three are thought to have a severe case and need to be treated immediately in order to prevent a lot of difficult things disease can inhibit in children,” he said.

Naglazyme is only available to Canadian patients through the federal government’s Special Access Program. The only provinces funding the treatment are Ontario, British Columbia and Quebec.

Isaac McFadyen has been receiving the treatment once a week for five years at the Hospital for Sick Children in Toronto. The cost of the treatment, produced by Biomarin, can range from $300,000 for a small individual to $1 million for a young adult each year.

It took lobbying to get Isaac’s treatment funded. The Isaac Foundation also works nationally and internationally to advocate for and support families dealing with MPS VI.

That’s why the McFadyens want to help the Mores. They’ve become accustomed to connecting with families internationally, but this is only the second time they’ve helped advocate for a family in Ontario.

It’s also “the first time that it’s someone as young as Isaac was when we first began this process,” McFadyen noted. “That’s why we created this charity and why we feel it’s important to have around. Not only to advocate, but we’ve been speaking with the family to kind of walk them through the stages of what to expect with this disease and what’s to come in the coming months. Also trying to give them hope that there is a treatment there and if we can get Jasper on it, that he has every opportunity of a wonderful quality of life and you know for him it will be a lifeboat until we can find a cure for this disease.”

Told of the More family’s circumstances, Ontario Premier Dalton McGuinty took a moment from his tour of the Port Hope Community Health Centre on Tuesday to say this spoke to him on a higher level than that of premier -rather, that of a father.

McGuinty said his heart goes out to the family in their difficulties, but he had no firsthand knowledge of the case and could not comment. He did suggest getting the Minister of Health, Deb Matthews, involved.

Matthews echoed the premier’s sentiments.

“I certainly certainly understand why this doesn’t sit right with Ontario families. I am following up to learn more about this drug and this particular situation,” she told QMI Agency on Wednesday. “I do know how important this is, and we want to do the right thing.”

Matthews said she will urge the ministry to examine the latest evidence on naglazyme.

“Maybe Lou knows something about it,” McGuinty added on Tuesday, referring to his host.

Northumberland-Quinte West MPP Lou Rinaldi nodded in the affirmative.

McFadyen confirmed he had updated Rinaldi on the events.

Rinaldi said yesterday that besides being aware of the case, all he knows is that the More’s local MPP John Wilkinson from the Perth-Wellington riding was working closely with the Ministry of Health.

This story about Jasper More gained some attention on Twitter during the past few days. McFadyen got a response from Matthews on Monday when he mentioned her Twitter handle, @Deb_Matthews in a tweet.

“I am looking into this. Thank you for bringing it to my attention,” she wrote.

McFadyen said Tuesday he was having no luck getting through to Matthews’s office, and found it difficult enough just to get someone to leave a message for her.

“I was told yesterday they’re looking into it and now I can’t get a hold of anybody today,” he said.

“What I do know is that there has been a very, very high call volume to Minister Matthews’s office today from people all across Ontario who are very concerned with this,” McFadyen adding, while also saying people told him they not only call the minister’s office, but contacted their local MPPs as well.

“There’s a lot of interest in this and it all seems to be very positive, understanding that this is a little boy that desperately needs to be on a treatment and it desperately needs to begin now,” McFadyen said.

After receiving tweets from McFadyen and others interested in the case, Matthews wrote to McFadyen again Tuesday night.

“We are all working hard on this case,” she said. “I know it is difficult, but know we are doing our best to move forward.”

An appeal to the rejection of funding was made on Tuesday.

What the More family is dealing with now, including lobbying for funding, takes the McFadyens back to when Isaac was diagnosed.

“It’s so, so hard to go through this process for a family and I know that they’re lost. You’re dealing with the news that your son has been diagnosed with this disease, and all the questions going on in your mind and adjusting to a new reality of life. It’s terribly overwhelming and I really feel for them right now,” McFadyen said.

“(Getting the funding) is something that we believe in, and if it were anybody else’s children, they would only expect the same. They would expect to have everything done in order to look after the well-being of their children. The fact that’s not being done right now is actually shocking and disappointing.”

jgard@northumberlandtoday.com

twitter.com/NT_jgard

– With files from Sheena Goodyear

Family Lobbies For Sick Tot’s Treatment

-661081_ORIGINALFormer Blue Jay Roy Halladay with Isaac McFadyen who was diagnosed with the very rare disease called MPS VI. (QMI Agency)Jeff Gard, QMI Agency

CAMPBELLFORD, Ont. – An Ontario family is lobbying for provincial funding so their two-year-old boy can get treatment for his rare and debilitating enzyme deficiency disease.

And they’re doing it with the help of another Ontario family who went through the same fight five years ago.

Seven-year-old Isaac McFadyen from Campbellford, Ont., is one of eight people Canada diagnosed with Maroteaux Lamy Syndrome (MPS VI). Only 1,100 worldwide have the progressive disease. Symptoms include stiffening joints, stunted growth, heart and airway disease, spinal cord compression and a shortened life span.

The McFadyens also know how much treatment has helped Isaac – a treatment he gets only because of provincial funding, which they had to lobby to get.

About five years after Isaac’s diagnosis, a Palmerston, Ont., family is going through a similar experience. Darren and Pam More’s two-year-old son Jasper was diagnosed with MPS VI six weeks ago. They learned Monday that Jasper was denied funding to receive the treatment.

“It’s shocking in our province right now that this is taking place. We do have precedent set with Isaac and it’s virtually an identical case,” said Andrew McFadyen, Issac’s father. “To me, it’s a travesty and it’s not representing equal access to health care for everybody.”

However, Health Minister Deb Matthews noted the laws in Ontario changed in 2006 to prevent politicians from choosing which drugs do or don’t get covered. Now, the decision rests with an executive officer who relies on a panel of experts that weights medical evidence.

“However, I do want to learn more about this and I need to understand the basis of the decision,” Matthews said.

While there’s no cure for MPS VI, there is the life-sustaining treatment available called Naglazyme, which provides patients with a synthetic version of the enzyme they are lacking by infusing small doses of it into the bloodstream.

The treatment can cost anywhere from $300,000 for a small individual to $1 million for a young adult each year.

“Studies are showing right now that kids that get on this treatment at a young age, basically where Jasper is, it gives them a better opportunity to prevent some of the side effects that come with the disease,” McFadyen said.

“Children diagnosed before age of three are thought to have a severe case and need to be treated immediately in order to prevent a lot of difficult things disease can inhibit in children.”

Naglazyme is only available to Canadian patients through the federal government’s Special Access Program. The only provinces funding the treatment are Ontario, British Columbia and Quebec.

Isaac has been receiving the treatment once a week for five years at the Hospital for Sick Children in Toronto.

Told of the More family’s circumstances, Ontario Premier Dalton McGuinty said his heart goes out to the family in their difficulties, but that he had no first-hand knowledge of the case and could not comment. He suggested getting in touch with Health Minister Deb Matthews.

Matthews echoed the premier’s sentiments.

“I certainly certainly understand why this doesn’t sit right with Ontario families. I am following up to learn more about this drug and this particular situation,” she told QMI Agency on Wednesday. “I do know how important this is, and we want to do the right thing.”

Matthews said she will urge the ministry to examine the latest evidence on naglazyme.

The Mores issued an appeal to the rejection of funding on Tuesday.

The McFadyens established The Isaac Foundation in 2006 to raise money for innovative research projects that aim to find a cure for MPS VI. They also help families touched by the disease.

– With files from Sheena Goodyear

Family Lobbies For Sick Tot's Treatment

-661081_ORIGINALFormer Blue Jay Roy Halladay with Isaac McFadyen who was diagnosed with the very rare disease called MPS VI. (QMI Agency)Jeff Gard, QMI Agency

CAMPBELLFORD, Ont. – An Ontario family is lobbying for provincial funding so their two-year-old boy can get treatment for his rare and debilitating enzyme deficiency disease.

And they’re doing it with the help of another Ontario family who went through the same fight five years ago.

Seven-year-old Isaac McFadyen from Campbellford, Ont., is one of eight people Canada diagnosed with Maroteaux Lamy Syndrome (MPS VI). Only 1,100 worldwide have the progressive disease. Symptoms include stiffening joints, stunted growth, heart and airway disease, spinal cord compression and a shortened life span.

The McFadyens also know how much treatment has helped Isaac – a treatment he gets only because of provincial funding, which they had to lobby to get.

About five years after Isaac’s diagnosis, a Palmerston, Ont., family is going through a similar experience. Darren and Pam More’s two-year-old son Jasper was diagnosed with MPS VI six weeks ago. They learned Monday that Jasper was denied funding to receive the treatment.

“It’s shocking in our province right now that this is taking place. We do have precedent set with Isaac and it’s virtually an identical case,” said Andrew McFadyen, Issac’s father. “To me, it’s a travesty and it’s not representing equal access to health care for everybody.”

However, Health Minister Deb Matthews noted the laws in Ontario changed in 2006 to prevent politicians from choosing which drugs do or don’t get covered. Now, the decision rests with an executive officer who relies on a panel of experts that weights medical evidence.

“However, I do want to learn more about this and I need to understand the basis of the decision,” Matthews said.

While there’s no cure for MPS VI, there is the life-sustaining treatment available called Naglazyme, which provides patients with a synthetic version of the enzyme they are lacking by infusing small doses of it into the bloodstream.

The treatment can cost anywhere from $300,000 for a small individual to $1 million for a young adult each year.

“Studies are showing right now that kids that get on this treatment at a young age, basically where Jasper is, it gives them a better opportunity to prevent some of the side effects that come with the disease,” McFadyen said.

“Children diagnosed before age of three are thought to have a severe case and need to be treated immediately in order to prevent a lot of difficult things disease can inhibit in children.”

Naglazyme is only available to Canadian patients through the federal government’s Special Access Program. The only provinces funding the treatment are Ontario, British Columbia and Quebec.

Isaac has been receiving the treatment once a week for five years at the Hospital for Sick Children in Toronto.

Told of the More family’s circumstances, Ontario Premier Dalton McGuinty said his heart goes out to the family in their difficulties, but that he had no first-hand knowledge of the case and could not comment. He suggested getting in touch with Health Minister Deb Matthews.

Matthews echoed the premier’s sentiments.

“I certainly certainly understand why this doesn’t sit right with Ontario families. I am following up to learn more about this drug and this particular situation,” she told QMI Agency on Wednesday. “I do know how important this is, and we want to do the right thing.”

Matthews said she will urge the ministry to examine the latest evidence on naglazyme.

The Mores issued an appeal to the rejection of funding on Tuesday.

The McFadyens established The Isaac Foundation in 2006 to raise money for innovative research projects that aim to find a cure for MPS VI. They also help families touched by the disease.

– With files from Sheena Goodyear

Ontario Ponies Up For Sick Tot’s Medical Bills

By Jeff Gard, QMI Agency – August 08, 2011

CAMPBELLFORD, Ont. – Jasper More, the two-year-old Palmerston, Ont., boy recently diagnosed with a rare and debilitating enzyme deficiency disease, will receive treatment through provincial government funding after all.

As reported Wednesday by QMI Agency, Jasper was diagnosed six weeks ago with Maroteaux Lamy Syndrome (MPS VI).

He is one of eight Canadians who has the progressive disease, and its symptoms include stiffening joints, stunted growth, heart and airway disease, spinal cord compression and a shortened life span. Only 1,100 people worldwide have MPS VI, for which there is no cure.

Darren More, Jasper’s dad, said he received a call Thursday from the family’s genetics doctor to inform them Jasper would receive the treatment Naglazyme through Canada’s Special Access Program and it will be funded by the Ontario government.

“It was absolutely breathtaking …literally breathtaking. I couldn’t breathe,” More said. “It’s such a huge weight off our shoulders. We’re so happy our child is going to get that treatment and have a chance at a normal lifestyle.”

Naglazyme is a treatment that provides patients with a synthetic version of the enzyme the disease’s sufferers lack by infusing small doses of it into the bloodstream. It can cost anywhere from $300,000 for a small individual to $1 million for a young adult each year.

Naglazyme is only available to Canadian patients through the federal government’s Special Access Program. The only provinces funding the treatment are Ontario, British Columbia and Quebec.

Jasper was originally denied funding for the treatment.

It was surprising news to a Campbellford, Ont., family. Andrew and Ellen McFadyen’s son Isaac, who is now seven, has been receiving the treatment for five years because of provincial funding, which they had to lobby to get. Isaac makes a weekly trip to the Hospital for Sick Children in Toronto for the treatment.

The McFadyens established The Isaac Foundation in 2006 to raise money for innovative research projects that aim to find a cure for MPS VI. They also help families touched by the disease.

Since Monday, the McFadyens helped the Mores lobby the government, and created awareness of the More case through social media, bringing it national attention.

“I certainly understand why this doesn’t sit right with Ontario families. I am following up to learn more about this drug and this particular situation,” Ontario Health Minister Deb Matthews told QMI Agency on Wednesday. “I do know how important this is, and we want to do the right thing.”

Andrew McFadyen heard the news through More.

“For Ellen and I, we’ve been through that and to experience with them in just a small way was very special,” he said.

McFadyen said the treatment for his son has made a world of difference.

“Essentially given him a new life,” he said. “We were told initially he wouldn’t make it to this age, but he has and right now he’s out playing with all of his friends like seven-year-olds should be doing. He has every chance in the world, like every kid should, and that’s all because of treatment. Jasper will have that chance now, too.”

The Ministry of Health could not be reached for comment Thursday.

 

Ontario Ponies Up For Sick Tot's Medical Bills

By Jeff Gard, QMI Agency – August 08, 2011

CAMPBELLFORD, Ont. – Jasper More, the two-year-old Palmerston, Ont., boy recently diagnosed with a rare and debilitating enzyme deficiency disease, will receive treatment through provincial government funding after all.

As reported Wednesday by QMI Agency, Jasper was diagnosed six weeks ago with Maroteaux Lamy Syndrome (MPS VI).

He is one of eight Canadians who has the progressive disease, and its symptoms include stiffening joints, stunted growth, heart and airway disease, spinal cord compression and a shortened life span. Only 1,100 people worldwide have MPS VI, for which there is no cure.

Darren More, Jasper’s dad, said he received a call Thursday from the family’s genetics doctor to inform them Jasper would receive the treatment Naglazyme through Canada’s Special Access Program and it will be funded by the Ontario government.

“It was absolutely breathtaking …literally breathtaking. I couldn’t breathe,” More said. “It’s such a huge weight off our shoulders. We’re so happy our child is going to get that treatment and have a chance at a normal lifestyle.”

Naglazyme is a treatment that provides patients with a synthetic version of the enzyme the disease’s sufferers lack by infusing small doses of it into the bloodstream. It can cost anywhere from $300,000 for a small individual to $1 million for a young adult each year.

Naglazyme is only available to Canadian patients through the federal government’s Special Access Program. The only provinces funding the treatment are Ontario, British Columbia and Quebec.

Jasper was originally denied funding for the treatment.

It was surprising news to a Campbellford, Ont., family. Andrew and Ellen McFadyen’s son Isaac, who is now seven, has been receiving the treatment for five years because of provincial funding, which they had to lobby to get. Isaac makes a weekly trip to the Hospital for Sick Children in Toronto for the treatment.

The McFadyens established The Isaac Foundation in 2006 to raise money for innovative research projects that aim to find a cure for MPS VI. They also help families touched by the disease.

Since Monday, the McFadyens helped the Mores lobby the government, and created awareness of the More case through social media, bringing it national attention.

“I certainly understand why this doesn’t sit right with Ontario families. I am following up to learn more about this drug and this particular situation,” Ontario Health Minister Deb Matthews told QMI Agency on Wednesday. “I do know how important this is, and we want to do the right thing.”

Andrew McFadyen heard the news through More.

“For Ellen and I, we’ve been through that and to experience with them in just a small way was very special,” he said.

McFadyen said the treatment for his son has made a world of difference.

“Essentially given him a new life,” he said. “We were told initially he wouldn’t make it to this age, but he has and right now he’s out playing with all of his friends like seven-year-olds should be doing. He has every chance in the world, like every kid should, and that’s all because of treatment. Jasper will have that chance now, too.”

The Ministry of Health could not be reached for comment Thursday.